Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual Meeting

  Idera Pharmaceuticals Announces Presentation at American Academy of
  Dermatology Annual Meeting

Business Wire

CAMBRIDGE, Mass. -- February 26, 2013

Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company developing
Toll-like receptor targeted drug candidates for the treatment of autoimmune
diseases, today announced a presentation of preclinical data will be made by
its collaborator, Dr. James G. Krueger of The Rockefeller University, at the
Late-Breaking Research Symposium during the American Academy of Dermatology
Annual Meeting being held March 1^st through 5^th, 2013, in Miami Beach,
Florida.

The details of the presentation are as follows:

Title: Novel Toll-Like Receptor Antagonists Strongly Decrease Expression of
IL-23-induced and Psoriasis Profile Genes in a Mouse Model

Date: Saturday, March 2^nd, 2013, at 10:00 am ET

Session: Late Breaking Research Symposium

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug
discovery platform to create immunomodulatory drug candidates and has a
clinical development program in autoimmune diseases. Additionally, Idera has a
collaboration with Merck & Co. for the use of TLR-targeted candidates as
vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. The
Company is also exploring its gene-silencing oligonucleotide (GSO) technology
for the purpose of inhibiting the expression of disease-promoting genes. For
more information, visit http://www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For
this purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates," "plans,"
"expects," "estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking statements. There
are a number of important factors that could cause Idera's actual results to
differ materially from those indicated by such forward-looking statements,
including whether Idera’s cash resources will be sufficient to fund the
Company’s continuing operations and the further development of the Company’s
autoimmune disease program; whether results obtained in preclinical studies
and early clinical trials will be indicative of results obtained in future
clinical trials; whether products based on Idera's technology will advance
into or through the clinical trial process on a timely basis or at all and
receive approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's products
receive approval, they will be successfully distributed and marketed; whether
the Company will be able to license any of its TLR target candidates on a
timely basis or at all; whether the Company's collaboration with Merck & Co,
Inc., will be successful; whether the patents and patent applications owned or
licensed by the Company will protect the Company's technology and prevent
others from infringing it; and such other important factors as are set forth
under the caption "Risk Factors" in Idera's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2012 which important factors are incorporated
herein by reference. Idera disclaims any intention or obligation to update any
forward-looking statements.

Contact:

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com